Proposal to Amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act
The Ministry of Health and Long-Term Care is proposing to reform the Ontario Drug Benefit (ODB) program in order to make it more efficient, effective and sustainable.
Proposed amendments ... Read More
27
Jul2015
19
Jun2015
INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the deadline for drugs to be listed on the February 2016 “Liste des médicaments". These meetings will be held between August 28 and September 11, 2015, inclusively.
Meetings will cover the following:
Discussion on clinical studies
Discussion ... Read More
12
Jun2015
The Minister of Health and Social Services has authorized three updates to the List of Medications covered by the basic prescription drug insurance plan and the List of Medications – Institutions in 2016: February 1, June 1 and October 3, 2016. Updates to the lists of medications for multisource generic ... Read More
27
May2015
The BC Ministry of Health recently wrote to manufacturers to communicate updates to its drug review process and reimbursement submission requirements.
Updates to the Drug Review Process include:
The Drug Benefit Council (DBC) will now screen drug submissions under review by CDR to determine if a full DBC review is necessary. If ... Read More
27
May2015
The Ontario Public Drug Programs Division (OPDP) recently announced amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act. The amendments include the establishment of a pricing framework for certain generic products approved for listing on the Ontario Drug Benefit (ODB) Formulary/Comparative Drug Index on or after April ... Read More
25
May2015
The Canadian Organization for Rare Disorders (CORD) announced Friday that it will help launch Canada's first ever Rare Disease Strategy on Monday, May 25th, at 10am in Ottawa on Parliament Hill.
This Strategy was prepared by CORD further to extensive consultations over the past year with various stakeholders, with input from patients, ... Read More
10
Apr2015
Please be advised that updates to the Manufacturer Submission Policy were published effective April 1, 2015 and can be found at: https://idbl.ab.bluecross.ca/idbl/PDFS/dbl_sec1_drug.pdf
Should Manufacturers require additional clarification regarding the published Manufacturer Submission Policy please contact Alberta Blue Cross, Scientific and Research Services at: submissions@ab.bluecross.ca
For more information, please see ... Read More
30
Mar2015
We recently participated in Mediaplanet Canada’s Rare Diseases campaign in which many industry leaders united to provide Canadians with a comprehensive view of Canada’s healthcare system and the policies that affect the lives of those living with or affected by rare disorders. The campaign was distributed through the National Post on ... Read More
14
Jan2015
QUEBEC
L’Institut national d’excellence en santé et en services sociaux (INESSS) has released the list of drug products submitted for the June 2015 “Liste des médicaments.”
Health professionals, citizens and patients and their associations and groups have until ... Read More
06
Nov2014
ONTARIO
Proposed Regulation Amendments to Establish a Pricing Framework for Generic Products
An Ontario Public Drug Programs Executive Officer Communication published on November 5, 2014 invites stakeholder comments on proposed amendments to O. Reg. 201/96 under the Ontario Drug Benefit Act. The proposed amendments would establish a pricing framework for ... Read More